Literature DB >> 15761492

Role of osteopontin in amplification and perpetuation of rheumatoid synovitis.

Guangwu Xu1, Hong Nie, Ningli Li, Wenxin Zheng, Dongqing Zhang, Guozhang Feng, Liqing Ni, Rong Xu, Jian Hong, Jingwu Z Zhang.   

Abstract

Osteopontin (OPN) is an extracellular matrix protein of pleiotropic properties and has been recently recognized as a potential inflammatory cytokine. In this study, we demonstrate, for the first time to our knowledge, that overexpression of OPN in synovial T cells is associated with local inflammatory milieu and that OPN acts as an important mediator in amplification and perpetuation of rheumatoid synovitis. The study revealed that mRNA expression of OPN was highly elevated in CD4(+) synovial T cells derived from patients with RA, which correlated with increased OPN concentrations in synovial fluid (SF). The pattern of OPN overexpression was confined to rheumatoid synovium and correlated with coexpression of selected OPN receptors in synovial T cells, including integrins alphav and beta1 and CD44. RA-derived SF stimulated the expression of OPN in T cells, which was attributable to IL-10 present in SF and abrogated by anti-IL-10 antibody. Among the more than 300 autoimmune and inflammatory response genes examined, OPN selectively induced the expression of proinflammatory cytokines and chemokines known to promote migration and recruitment of inflammatory cells. Furthermore, it was evident that OPN activated transcription factor NF-kappaB in mononuclear cells. The study has important implications for understanding the role of OPN in rheumatoid synovitis and other inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15761492      PMCID: PMC1059449          DOI: 10.1172/JCI23273

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors:  S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

Review 3.  Review: Free radicals, antioxidants, and the immune system.

Authors:  J A Knight
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

4.  Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts.

Authors:  P K Petrow; K M Hummel; J Schedel; J K Franz; C L Klein; U Müller-Ladner; J Kriegsmann; P L Chang; C W Prince; R E Gay; S Gay
Journal:  Arthritis Rheum       Date:  2000-07

5.  Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis.

Authors:  J Furuzawa-Carballeda; J Alcocer-Varela
Journal:  Scand J Immunol       Date:  1999-08       Impact factor: 3.487

6.  Focally regulated endothelial proliferation and cell death in human synovium.

Authors:  D A Walsh; M Wade; P I Mapp; D R Blake
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

7.  HLA-DR4Dw4-restricted T cell recognition of self antigen(s) in the rheumatoid synovial compartment.

Authors:  D Devereux; R E O'Hehir; J McGuire; W C van Schooten; J R Lamb
Journal:  Int Immunol       Date:  1991-07       Impact factor: 4.823

8.  Elevated interleukin-10 levels in patients with rheumatoid arthritis.

Authors:  J J Cush; J B Splawski; R Thomas; J E McFarlin; H Schulze-Koops; L S Davis; K Fujita; P E Lipsky
Journal:  Arthritis Rheum       Date:  1995-01

9.  Adhesion molecule expression in human synovial tissue.

Authors:  B A Johnson; G K Haines; L A Harlow; A E Koch
Journal:  Arthritis Rheum       Date:  1993-02

10.  The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.

Authors:  E C Rankin; E H Choy; D Kassimos; G H Kingsley; A M Sopwith; D A Isenberg; G S Panayi
Journal:  Br J Rheumatol       Date:  1995-04
View more
  47 in total

Review 1.  The impact of the extracellular matrix on inflammation.

Authors:  Lydia Sorokin
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

2.  Life sciences and biotechnology in China.

Authors:  Zhu Chen; Hong-Guang Wang; Zhao-Jun Wen; Yihuang Wang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

Review 3.  Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.

Authors:  T L Rothstein; B Guo
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

4.  Cord blood levels of osteopontin as a phenotype marker of gestational age and neonatal morbidities.

Authors:  Kyoung Eun Joung; Helen Christou; Kyung-Hee Park; Christos S Mantzoros
Journal:  Obesity (Silver Spring)       Date:  2013-12-04       Impact factor: 5.002

Review 5.  Studying non-mammalian models? Not a fool's ERRand!

Authors:  Pierre-Luc Bardet; Vincent Laudet; Jean-Marc Vanacker
Journal:  Trends Endocrinol Metab       Date:  2006-03-31       Impact factor: 12.015

Review 6.  siRNA-based therapeutic approaches for rheumatic diseases.

Authors:  Florence Apparailly; Christian Jorgensen
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

7.  Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis.

Authors:  Anne M Seier; Andreas C Renkl; Guido Schulz; Tanja Uebele; Anca Sindrilaru; Sebastian Iben; Lucy Liaw; Shigeyuki Kon; Toshimitsu Uede; Johannes M Weiss
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

8.  B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways.

Authors:  Benchang Guo; Joseph R Tumang; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

9.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

10.  Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis.

Authors:  Jiamu Du; Sheng Hou; Chen Zhong; Zheng Lai; Hui Yang; Jianxin Dai; Dapeng Zhang; Hao Wang; Yajun Guo; Jianping Ding
Journal:  J Mol Biol       Date:  2008-07-31       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.